Nov. 28, 2018
ZEISS announced the U.S. launch of Total Keratometry (TK) for IOLMaster 700, at the Annual Meeting of the American Academy of Ophthalmology in October 2018 in Chicago.
ZEISS says the technology offers cataract surgeons “the opportunity to replace assumptions about the posterior corneal surface with precise measurements, which can help improve outcomes.” TK was developed to be compatible with standard formulas and existing IOL constants, thus allowing surgeons to detect outlier cases with minimal disruptions to existing workflows. The device also includes two new Barrett formulas incorporating the new TK value.
In addition, the company recently announced the FDA approval for ReLEx SMILE to expand myopia treatment to patients with astigmatism. SMILE utilizes the high-precision femtosecond laser VisuMax to create a lenticule inside the cornea and access incision in a single treatment step. With its outstanding cutting precision and exceptional speed, the minimally invasive VisuMax is an ideal platform for advanced corneal surgery.
“The expansion of myopia treatment to patients with astigmatism is a significant milestone in refractive technology, enabling current and future SMILE surgeons to expand their patient base, paving the way for a new generation of refractive surgery patients,” says James V. Mazzo, global president, Ophthalmic Devices, at Carl Zeiss Meditec.
The technology behind SMILE was recently featured in the Scientific Background on the Nobel Prize in Physics 2018. Dr. Gérard Mourou and Dr. Donna Strickland were awarded the Nobel Prize for their method to generate high-intensity ultrashort optical pulses.
“Procedures and technologies developed by ZEISS such as SMILE help doctors to improve the vision of many people,” says Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec, “which is why we have secured our intellectual property around it against any infringement.”
ZEISS is also introducing the Advanced Nerve and Glaucoma Imaging (A N G I) Network. Led by an independent group of doctors and clinical researchers worldwide in the field of glaucoma, A NG I Network’s goal is to foster global collaborations to elevate the latest research in glaucoma and optic nerve diseases. “ANGI is the surest way to advance the field, to enhance diagnosis and the assessment of the efficacy of our treatments,” says NYU Langone Eye Center Director Joel S. Schuman, MD, FACS.
A N G I Network consists of leading researchers in the fields of neuro-ophthalmology and glaucoma, who use the PLEX Elite 9000, a Swept-Source OCT providing imaging of the eye, from the vitreous to the choroid. ZEISS describes PLEX Elite as “an exciting cutting-edge technology that has the potential to advance the future of medicine through clinical research by the A N G I Network.”
“Collaborating with leading doctors, researchers and practitioners is at the core of our innovation process,” Monz says. “A N G I Network is one of the many ways we partner to help provide technologies and innovations to advance research and discovery to accelerate the development of new clinical applications for disease management.”